Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


New Antiviral Drug Inhibits Epidemic SARS, MERS & More


 

A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators recently reported in Science Translational Medicine. The findings support further development of the drug candidate for treating and preventing current coronavirus infections and potential future epidemic outbreaks.

Coronaviruses are a genetically diverse family of viruses that infect birds and mammals, with most coronavirus strains limited to infecting only certain hosts. Human coronaviruses, for example, cause up to 30 percent of common colds.

In the last 15 years, however, coronaviruses have demonstrated their ability to jump into new species. Zoonotic (animal) coronaviruses have infected humans, causing severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), severe diseases with high mortality rates ranging from 10 percent for SARS to 40 percent for MERS. The MERS-coronavirus continues to cause new infections in the Middle East.

"There's a real concern that the MERS coronavirus could escape broadly when millions of people visit Saudi Arabia for the Hajj," Mark Denison, MD, the Craig-Weaver Professor of Pediatrics and professor of Pathology, Microbiology and Immunology at Vanderbilt University School of Medicine, said of the event happening at the beginning of September. But to date, there has been no effective antiviral drug for any known coronavirus, he noted.

Denison and his team at Vanderbilt have studied the basic biology of coronaviruses for more than 20 years. In an effort to find chemical tools that would allow them to probe viral replication, graduate student Brett Case screened a series of compounds selected and provided by Gilead Sciences. Case demonstrated that one of the compounds was highly active against coronaviruses in cultured cells. The finding was a surprise, Denison said, because compounds in the same class (nucleoside analogs) have normally failed to inhibit coronavirus replication. The compound, called GS-5734, is currently in clinical development for treatment of Ebola virus disease.

Denison's longtime collaborator Ralph Baric, PhD, at the University of North Carolina and his team demonstrated that GS-5734 inhibits SARS-coronavirus and MERS-coronavirus replication in multiple in vitro systems, including cultures of primary human airway epithelial cells, which are the cells infected by respiratory coronaviruses. The researchers also showed that GS-5734 was effective against a circulating human coronavirus, bat coronaviruses, and bat coronaviruses that are considered "pre-pandemic" because they can infect cultured human cells.

Using a mouse model of SARS, the investigators demonstrated that both prophylactic and early therapeutic administration of GS-5734 reduced viral load in the lungs and improved respiratory functions. "This compound shows broad activity against a variety of human and animal coronaviruses and represents an exciting potential therapeutic for a family of viruses prone to emergence from animal reservoirs," Denison said.

Denison and his team at Vanderbilt will continue to use the compound "as a probe to try to understand the biology of the virus, how and why this drug works, and to identify new targets for inhibiting coronaviruses," he said.

"This is an exciting example of how pursuing fundamental research to understand the mechanisms of virus replication and pathogenesis can lead to an important compound with therapeutic potential."

WEB:
The Denison Lab at Vanderbilt
Science Translational Medicine Article

 
Share:

Related Articles:


Recent Articles

Physicians Discuss Opioids, Scope of Practice and More During TMA Annual Meeting

State's Largest Professional Organization for Doctors Announces 2018-2019 Officers

Read More

Tristar Centennial Medical Center Announces Construction Of New Multi-Level Parking Garage

Tristar Centennial Medical Center is pleased to announce the construction of a new multi-level parking garage that will be located at the corner of 23rd Avenue and Patterson Street.

Read More

Healthcare Redesigned

Nature and sustainability are key in today's updated medical facilities.

Read More

McWhorter Society Luncheon Honors Healthcare Luminaries

The annual McWhorter Society Luncheon at Belmont University celebrated healthcare accomplishments by honoring Gov. Winfield C. Dunn and announcing the 2018 inductees into the Tennessee Health Care Hall of Fame.

Read More

Mazzetti+GBA Launches Tool for Healthcare Architects, Engineers

A new app unveiled in Nashville by Mazzetti+GBA supports project planning for healthcare architects, engineers

Read More

Making Medical Devices Lighter, Stronger, Safer

Locally company Can-Do National Tape is using their expertise in adhesives to make medical device and design lighter, stronger, safer.

Read More

NMGMA: 10 Minute Takeaway

You can't manage what you can't measure ... KraftCPA's Lucy Carter shares the basic principles of medical office accounting.

Read More

Insights from Inside the Beltway

As EBG celebrates their first anniversary in Nashville, senior strategists from the firm's D.C. office share insights from the nation's capital.

Read More

Physician Spotlight: TennCare CMO Victor Wu

TennCare CMO launches programs aimed at improving health of Tennessee's Medicaid recipients.

Read More

Making the Grade

Men's Health Report card shows improvement in key markers.

Read More

Email Print
 
 

 

 


Tags:
Antiviral Drug Candidate, Brett Case, Coronavirus, GS-5734, Mark Denison, MERS, Ralph Baric, SARS, Vanderbilt University Medical Center, VUMC
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: